Carregant...
How I treat a refractory myeloma patient who is not eligible for a clinical trial
Myeloma patients not eligible for clinical trials have many treatment options. Choosing the next best therapy starts with careful assessment of the biology and dynamics of the disease at relapse, as well as the condition and situation of the patient. Fit patients should be considered for triplet reg...
Guardat en:
| Publicat a: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913488/ https://ncbi.nlm.nih.gov/pubmed/31808850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000016 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|